Back to Search Start Over

Artificial intelligence and leukocyte epigenomics: Evaluation and prediction of late-onset Alzheimer's disease.

Authors :
Bahado-Singh RO
Vishweswaraiah S
Aydas B
Yilmaz A
Metpally RP
Carey DJ
Crist RC
Berrettini WH
Wilson GD
Imam K
Maddens M
Bisgin H
Graham SF
Radhakrishna U
Source :
PloS one [PLoS One] 2021 Mar 31; Vol. 16 (3), pp. e0248375. Date of Electronic Publication: 2021 Mar 31 (Print Publication: 2021).
Publication Year :
2021

Abstract

We evaluated the utility of leucocyte epigenomic-biomarkers for Alzheimer's Disease (AD) detection and elucidates its molecular pathogeneses. Genome-wide DNA methylation analysis was performed using the Infinium MethylationEPIC BeadChip array in 24 late-onset AD (LOAD) and 24 cognitively healthy subjects. Data were analyzed using six Artificial Intelligence (AI) methodologies including Deep Learning (DL) followed by Ingenuity Pathway Analysis (IPA) was used for AD prediction. We identified 152 significantly (FDR p<0.05) differentially methylated intragenic CpGs in 171 distinct genes in AD patients compared to controls. All AI platforms accurately predicted AD with AUCs ≥0.93 using 283,143 intragenic and 244,246 intergenic/extragenic CpGs. DL had an AUC = 0.99 using intragenic CpGs, with both sensitivity and specificity being 97%. High AD prediction was also achieved using intergenic/extragenic CpG sites (DL significance value being AUC = 0.99 with 97% sensitivity and specificity). Epigenetically altered genes included CR1L & CTSV (abnormal morphology of cerebral cortex), S1PR1 (CNS inflammation), and LTB4R (inflammatory response). These genes have been previously linked with AD and dementia. The differentially methylated genes CTSV & PRMT5 (ventricular hypertrophy and dilation) are linked to cardiovascular disease and of interest given the known association between impaired cerebral blood flow, cardiovascular disease, and AD. We report a novel, minimally invasive approach using peripheral blood leucocyte epigenomics, and AI analysis to detect AD and elucidate its pathogenesis.<br />Competing Interests: The authors have read the journal’s policy and have the following competing interest: BA is a paid employee of Meridian HealthComms Ltd. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Details

Language :
English
ISSN :
1932-6203
Volume :
16
Issue :
3
Database :
MEDLINE
Journal :
PloS one
Publication Type :
Academic Journal
Accession number :
33788842
Full Text :
https://doi.org/10.1371/journal.pone.0248375